FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jyrki Taskinen

Research Profile

Chemicals & Drugs

Concepts & Ideas

Procedures

Living Beings

Anatomy

Microsomes, Liver

Phenomena

Magnetic Resonance Spectroscopy

Co-author Network

Publications

TOP 3
Katriina Itäaho; Sami Alakurtti; Jari Yli-Kauhaluoma; Jyrki Taskinen; Michael W H Coughtrie; Risto Kostiainen
Regioselective sulfonation of dopamine by SULT1A3 in vitro provides a molecular explanation for the preponderance of dopamine-3-O-sulfate in human blood circulation.
Julius Sipilä; Harri Nurmi; Ann Marie Kaukonen; Jouni Hirvonen; Jyrki Taskinen; Jari Yli-Kauhaluoma
A modification of the Hammett equation for predicting ionisation constants of p-vinyl phenols.
Leena Luukkanen; Jyrki Taskinen; Mika Kurkela; Risto Kostiainen; Jouni Hirvonen; Moshe Finel
Kinetic characterization of the 1A subfamily of recombinant human UDP-glucuronosyltransferases.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jyrki Taskinen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Katriina Itäaho; Sami Alakurtti; Jari Yli-Kauhaluoma; Jyrki Taskinen; Michael W H Coughtrie; Risto Kostiainen
Regioselective sulfonation of dopamine by SULT1A3 in vitro provides a molecular explanation for the preponderance of dopamine-3-O-sulfate in human blood circulation.
Biochemical pharmacology 2007;74(3):504-10.
2005: Julius Sipilä; Harri Nurmi; Ann Marie Kaukonen; Jouni Hirvonen; Jyrki Taskinen; Jari Yli-Kauhaluoma
A modification of the Hammett equation for predicting ionisation constants of p-vinyl phenols.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2005;25(4-5):417-25.
2005: Leena Luukkanen; Jyrki Taskinen; Mika Kurkela; Risto Kostiainen; Jouni Hirvonen; Moshe Finel
Kinetic characterization of the 1A subfamily of recombinant human UDP-glucuronosyltransferases.
Drug metabolism and disposition: the biological fate of chemicals 2005;33(7):1017-26.
2004: Eivor Elovaara; Jouni Mikkola; Leena Luukkanen; Laurence Antonio; Sylvie Fournel-Gigleux; Brian Burchell; Jacques Magdalou; Jyrki Taskinen
Assessment of catechol induction and glucuronidation in rat liver microsomes.
Drug metabolism and disposition: the biological fate of chemicals 2004;32(12):1426-33.
2004: Mika Kurkela; Antti Siiskonen; Moshe Finel; Päivi Tammela; Jyrki Taskinen; Pia Vuorela
Microplate screening assay to identify inhibitors of human catechol-O-methyltransferase.
Analytical biochemistry 2004;331(1):198-200.
2004: Julius Sipilä; Jyrki Taskinen
CoMFA modeling of human catechol O-methyltransferase enzyme kinetics.
Journal of chemical information and computer sciences 2004;44(1):97-104.
2003: Jyrki Taskinen; Jouko Yliruusi
Prediction of physicochemical properties based on neural network modelling.
Advanced drug delivery reviews 2003;55(9):1163-83.
2003: Julius Sipilä; Alan M Hood; Michael W H Coughtrie; Jyrki Taskinen
CoMFA modeling of enzyme kinetics: K(m) values for sulfation of diverse phenolic substrates by human catecholamine sulfotransferase SULT1A3.
Journal of chemical information and computer sciences 2003;43(5):1563-9.
2003: Jyrki Taskinen; Brian T Ethell; Pia Pihlavisto; Alan M Hood; Brian Burchell; Michael W H Coughtrie
Conjugation of catechols by recombinant human sulfotransferases, UDP-glucuronosyltransferases, and soluble catechol O-methyltransferase: structure-conjugation relationships and predictive models.
Drug metabolism and disposition: the biological fate of chemicals 2003;31(9):1187-97.
2003: Mika Kurkela; J Arturo García-Horsman; Leena Luukkanen; Saila Mörsky; Jyrki Taskinen; Marc Baumann; Risto Kostiainen; Jouni Hirvonen; Moshe Finel
Expression and characterization of recombinant human UDP-glucuronosyltransferases (UGTs). UGT1A9 is more resistant to detergent inhibition than other UGTs and was purified as an active dimeric enzyme.
The Journal of biological chemistry 2003;278(6):3536-44.
2002: Helena Keski-Hynnilä; Mika Kurkela; Eivor Elovaara; Laurence Antonio; Jacques Magdalou; Leena Luukkanen; Jyrki Taskinen; Risto Kostiainen
Comparison of electrospray, atmospheric pressure chemical ionization, and atmospheric pressure photoionization in the identification of apomorphine, dobutamine, and entacapone phase II metabolites in biological samples.
Analytical chemistry 2002;74(14):3449-57.
2002: Sanna Kaivosaari; Jarmo S Salonen; Jyrki Taskinen
N-Glucuronidation of some 4-arylalkyl-1H-imidazoles by rat, dog, and human liver microsomes.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(3):295-300.
2002: Laurence Antonio; Grillasca Joel; Jyrki Taskinen; Eivor Elovaara; Brian Burchell; Marie-Helene Piet; Brian T Ethell; Mohamed Ouzzine; Sylvie Fournel-Gigleux; Jacques Magdalou
Characterization of catechol glucuronidation in rat liver.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(2):199-207.
2001: Jan Tois; Robert Franzén; Olli Aitio; Into Laakso; Jarmo Huuskonen; Jyrki Taskinen
Solid-phase bromination and Suzuki coupling of 2-carboxyindoles.
Combinatorial chemistry & high throughput screening 2001;4(6):521-4.
2001: Helena Keski-Hynnilä; K Raanaa; M Forsberg; Pekka T Männistö; Jyrki Taskinen; Risto Kostiainen
Quantitation of entacapone glucuronide in rat plasma by on-line coupled restricted access media column and liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Biomedical sciences and applications 2001;759(2):227-36.
2001: Leena Luukkanen; Jouni Mikkola; T Forsman; P Taavitsainen; Jyrki Taskinen; Eivor Elovaara
Glucuronidation of 1-hydroxypyrene by human liver microsomes and human UDP-glucuronosyltransferases UGT1A6, UGT1A7, and UGT1A9: development of a high-sensitivity glucuronidation assay for human tissue.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(8):1096-101.
2001: Sanna Kaivosaari; Jarmo S Salonen; J Mortensen; Jyrki Taskinen
High-performance liquid chromatographic method combining radiochemical and ultraviolet detection for determination of low activities of uridine 5'-diphosphate-glucuronosyltransferase.
Analytical biochemistry 2001;292(2):178-87.
2001: P Lautala; Ismo Ulmanen; Jyrki Taskinen
Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase.
Molecular pharmacology 2001;59(2):393-402.
2000: Helena Keski-Hynnilä; K Raana; Jyrki Taskinen; Risto Kostiainen
Direct analysis of nitrocatechol-type glucuronides in urine by capillary electrophoresis-electrospray ionisation mass spectrometry and tandem mass spectrometry.
Journal of chromatography. B, Biomedical sciences and applications 2000;749(2):253-63.
2000: P Lautala; Brian T Ethell; Jyrki Taskinen; Brian Burchell
The specificity of glucuronidation of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(11):1385-9.
2000: T Forsman; P Lautala; K Lundström; K Monastyrskaia; Mohamed Ouzzine; Brian Burchell; Jyrki Taskinen; Ismo Ulmanen
Production of human UDP-glucuronosyltransferases 1A6 and 1A9 using the Semliki Forest virus expression system.
Life sciences 2000;67(20):2473-84.
1999: R Dajani; Anne Cleasby; M Neu; Alan J Wonacott; Harren Jhoti; A M Hood; S Modi; A Hersey; Jyrki Taskinen; R M Cooke; GR Manchee; Michael W H Coughtrie
X-ray crystal structure of human dopamine sulfotransferase, SULT1A3. Molecular modeling and quantitative structure-activity relationship analysis demonstrate a molecular basis for sulfotransferase substrate specificity.
The Journal of biological chemistry 1999;274(53):37862-8.
1999: P Lautala; Ismo Ulmanen; Jyrki Taskinen
Radiochemical high-performance liquid chromatographic assay for the determination of catechol O-methyltransferase activity towards various substrates.
Journal of chromatography. B, Biomedical sciences and applications 1999;736(1-2):143-51.
1999: Helena Keski-Hynnilä; Leena Luukkanen; Jyrki Taskinen; Risto Kostiainen
Mass spectrometric and tandem mass spectrometric behavior of nitrocatechol glucuronides: a comparison of atmospheric pressure chemical ionization and electrospray ionization.
Journal of the American Society for Mass Spectrometry 1999;10(6):537-45.
1999: Leena Luukkanen; Ilkka Kilpeläinen; Heli Kangas; P Ottoila; Eivor Elovaara; Jyrki Taskinen
Enzyme-assisted synthesis and structural characterization of nitrocatechol glucuronides.
Bioconjugate chemistry 1999;10(1):150-4.
1998: Jarmo Huuskonen; M Salo; Jyrki Taskinen
Aqueous solubility prediction of drugs based on molecular topology and neural network modeling.
Journal of chemical information and computer sciences 1998;38(3):450-6.
1997: P Lautala; M Kivimaa; Hannele Salomies; Eivor Elovaara; Jyrki Taskinen
Glucuronidation of entacapone, nitecapone, tolcapone, and some other nitrocatechols by rat liver microsomes.
Pharmaceutical research 1997;14(10):1444-8.
1997: M Orama; P Tilus; Jyrki Taskinen; T Lotta
Iron(III)-chelating properties of the novel catechol O-methyltransferase inhibitor entacapone in aqueous solution.
Journal of pharmaceutical sciences 1997;86(7):827-31.
1997: Jarmo Huuskonen; M Salo; Jyrki Taskinen
Neural network modeling for estimation of the aqueous solubility of structurally related drugs.
Journal of pharmaceutical sciences 1997;86(4):450-4.
1997: Leena Luukkanen; Eivor Elovaara; P Lautala; Jyrki Taskinen; Harri Vainio
Characterization of 1-hydroxypyrene as a novel marker substrate of 3-methylcholanthrene-inducible phenol UDP-glucuronosyltransferase(s).
Pharmacology & toxicology 1997;80(3):152-8.
1997: T Salminen; A Pulli; Jyrki Taskinen
Relationship between immobilised artificial membrane chromatographic retention and the brain penetration of structurally diverse drugs.
Journal of pharmaceutical and biomedical analysis 1997;15(4):469-77.
1995: Ritva Niemelä; Leena Penttilä; A Seppo; Jari Helin; Anne Leppänen; Jarkko Räbinä; L Uusitalo; Hannu Maaheimo; Jyrki Taskinen; C E Costello
Enzyme-assisted synthesis of a bivalent high-affinity dodecasaccharide inhibitor of mouse gamete adhesion. The length of the chains carrying distal alpha 1,3-bonded galactose residues is critical.
FEBS letters 1995;367(1):67-72.
1995: T Lotta; J Vidgren; Carola Gabriella Tilgmann; Ismo Ulmanen; Krister Melén; Ilkka Julkunen; Jyrki Taskinen
Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme.
Biochemistry 1995;34(13):4202-10.
1994: Piero Pollesello; M Ovaska; J Kaivola; Carola Gabriella Tilgmann; K Lundström; Nisse Kalkkinen; Ismo Ulmanen; E Nissinen; Jyrki Taskinen
Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study.
The Journal of biological chemistry 1994;269(46):28584-90.
1993: T Wikberg; P Ottoila; Jyrki Taskinen
Identification of major urinary metabolites of the catechol-O-methyltransferase inhibitor entacapone in the dog.
European journal of drug metabolism and pharmacokinetics 1993;18(4):359-67.
1993: T Wikberg; Jyrki Taskinen
Identification of major metabolites of the catechol-O-methyltransferase inhibitor nitecapone in the rat and dog.
Drug metabolism and disposition: the biological fate of chemicals 1993;21(2):325-33.
1993: T Wikberg; A Vuorela; P Ottoila; Jyrki Taskinen
Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans.
Drug metabolism and disposition: the biological fate of chemicals 1993;21(1):81-92.
1992: T Lotta; Jyrki Taskinen; R Bäckström; E Nissinen
PLS modelling of structure-activity relationships of catechol O-methyltransferase inhibitors.
Journal of computer-aided molecular design 1992;6(3):253-72.
1992: Pekka T Männistö; Ismo Ulmanen; K Lundström; Jyrki Taskinen; J Tenhunen; Carola Gabriella Tilgmann; Seppo Kaakkola
Characteristics of catechol O-methyl-transferase (COMT) and properties of selective COMT inhibitors.
Progress in drug research. Fortschritte der Arzneimittelforschung. Progrès des recherches pharmaceutiques 1992;39():291-350.
1991: P Ottoila; E Pakkala; C Karlsson; Jyrki Taskinen
Determination of nitecapone and (13C6)nitecapone in human plasma by gas chromatography/mass spectrometry.
Biological mass spectrometry 1991;20(12):771-6.
1991: T Wikberg; Jyrki Taskinen
Determination of a catechol-O-methyltransferase inhibitor, nitecapone, in human plasma and urine by liquid chromatography.
Journal of pharmaceutical and biomedical analysis 1991;9(1):59-64.
1991: M Ovaska; Jyrki Taskinen
A model for human cardiac troponin C and for modulation of its Ca2+ affinity by drugs.
Proteins 1991;11(2):79-94.
1991: Jyrki Taskinen; T Wikberg; P Ottoila; L Kanner; T Lotta; A Pippuri; R Bäckström
Identification of major metabolites of the catechol-O-methyltransferase-inhibitor nitecapone in human urine.
Drug metabolism and disposition: the biological fate of chemicals 1991;19(1):178-83.
1988: Pekka T Männistö; Jyrki Taskinen; P Ottoila; A Solkinen; A Vuorela; S Nykänen
Fate of single oral doses of erythromycin acistrate, erythromycin stearate and pelleted erythromycin base analysed by mass-spectrometry in plasma of healthy human volunteers.
The Journal of antimicrobial chemotherapy 1988;21 Suppl D():33-43.
1988: Jyrki Taskinen; P Ottoila
Hydrolysis of 2'-esters of erythromycin.
The Journal of antimicrobial chemotherapy 1988;21 Suppl D():1-8.
1987: P Ottoila; Jyrki Taskinen
Quantitative determination of erythromycin 2'-ethylsuccinate in human plasma by fast atom bombardment mass spectrometry.
Biomedical & environmental mass spectrometry 1987;14(11):659-62.
1985: M Marvola; A Kannikoski; Jyrki Taskinen; P Ottoila
Assessment of bioavailability of experimental single-unit sustained release tablets of verapamil hydrochloride using the stable isotope technique.
The Journal of pharmacy and pharmacology 1985;37(11):766-70.
1982: E Nissinen; Jyrki Taskinen
Simultaneous determination of carbidopa, levodopa and 3,4-dihydroxyphenyl-acetic acid using high-performance liquid chromatography with electrochemical detection.
Journal of chromatography 1982;231(2):459-62.
1982: P Ottoila; Jyrki Taskinen; A Sothmann
Quantitative determination of nitroglycerin in human plasma by capillary gas chromatography negative ion chemical ionization mass spectrometry.
Biomedical mass spectrometry 1982;9(3):108-10.
1981: P Ottoila; Jyrki Taskinen
Determination of biperiden in human serum by glass capillary gas chromatography with isothermal splitless injection and nitrogen-sensitive detection.
Journal of chromatography 1981;226(2):488-91.